Table 4 Endothelial function in patients with and without major adverse cardiovascular events

Reactive hyperemia index

0.36

 4–24 h

1.62 (1.33–1.96)

1.65 (1.52–1.80)

 POD3–5

1.88 (1.64–2.16)

1.72 (1.58–1.89)

L-arginine; μmol.l^− 1

0.96

 4–24 h

49.54 (43.16–55.91)

58.73 (53.40–64.07)

 POD3–5

65.66 (52.57–78.76)

74.64 (68.99–80.30)

ADMA; μmol.l^− 1

0.24

 4–24 h

0.43 (0.35–0.51)

0.37 (0.33–0.41)

 POD3–5

0.44 (0.33–0.55)

0.42 (0.38–0.46)

L-arginine/ADMA

0.21

 4–24 h

117.55 (95.21–145.15)

164.51 (145.79–185.62)

 POD3–5

155.04 (112.88–212.96)

181.49 (159.16–206.95)

BH₄; nmol.l^− 1

0.53

 4–24 h

8.75 (6.99–10.52)

7.69 (6.94–8.44)

 POD3–5

6.70 (5.47–7.92)

6.41 (5.48–7.35)

BH₂; nmol.l⁻¹

0.92

 4–24 h

4.85 (3.54–6.63)

3.95 (3.50–4.46)

 POD3–5

4.46 (3.44–5.77)

3.57 (3.26–3.90)

BH₂/BH₄

0.88

 4–24 h

0.59 (0.41–0.85)

0.56 (0.47–0.66)

 POD3–5

0.70 (0.49–0.99)

0.67 (0.53–0.85)

BH₂and biopterin metabolites; nmol.l^− 1

0.97

 4–24 h

13.74 (11.42–16.52)

11.59 (10.63–12.64)

 POD3–5

11.22 (9.65–13.05)

9.58 (8.66–10.61)